There's no secret nor secret recipe. It's not a secret magic potion. The question around dosing is due the combination of change between trials, change within trials, known DLE's, opacity, and implications. The opacity continues, and we'll just have to wait for trial results and future medical presentations. Not uncommon in biotech.
If anything is clear from the A2-73 data it is that high concentration is the absolute most important factor for positive response.
Dose and concentration is inextricably linked and undeniably stated by Anavex.
Understanding and questioning those relationships in the light of the low doses apparently administered in current controlled trials seems important to the Anavex investment thesis.
Dr.M is using High and Low doses as "place holders". They are trade secrets, hidden for the interests of the company AND shareholders. True for both Alz trial and PDD trial. Or to quote Dr.M, "...Don't specify the dose because we want to maintain complete blinding."
Also, as patients come off trial, dosages can be completely different levels, as has been discussed here.
Dr.M is using High and Low doses as "place holders". They are trade secrets, hidden for the interests of the company AND shareholders. True for both Alz trial and PDD trial. Or to quote Dr.M, "...Don't specify the dose because we want to maintain complete blinding."
Also, as patients come off trial, dosages can be completely different levels, as has been discussed here.
News 
Market Data 
Discover 
